Natural products as sources of new drugs over the last 25 years.
By D. Newman, G. Cragg. Journal of Natural Products, 2007
5,504 citations recorded by the source corpus.
This review is an updated and expanded version of two prior reviews that were published in this journal in 1997 and 2003. In the case of all approved agents the time frame has been extended to include the 251/2 years from 01/1981 to 06/2006 for all diseases worldwide and from 1950 (earliest so far identified) to 06/2006 for all approved antitumor drugs worldwide. We have continued to utilize our secondary subdivision of a "natural product mimic" or "NM" to join the original primary divisions. From the data presented, the utility of natural products as sources of novel structures, but not necessarily the final drug entity, is still alive and well. Thus, in the area of cancer, over the time frame from around the 1940s to date, of the 155 small molecules, 73% are other than "S" (synthetic), with 47% actually being either natural products or directly derived therefrom. In other areas, the influence of natural product structures is quite marked, with, as expected from prior information, the antiinfective area being dependent on natural products and their structures. Although combinatorial chemistry techniques have succeeded as methods of optimizing structures and have, in fact, been used in the optimization of many recently approved agents, we are able to identify only one de novo combinatorial compound approved as a drug in this 25 plus year time frame. We wish to draw the attention of readers to the rapidly evolving recognition that a significant number of natural product drugs/leads are actually produced by microbes and/or microbial interactions with the "host from whence it was isolated", and therefore we consider that this area of natural product research should be expanded significantly.
Subfields: Biotechnology, Molecular Biology, Pharmacology
View Paper: https://www.semanticscholar.org/paper/ce752c365a3b9e0e34010eadaa362138d2248c63
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biotechnology
In Molecular Biology
- Bharat B. Aggarwal
- A. Kunnumakkara
- A. Harvey
- Gisbert Schneider
- D. Kennedy
- E. Wightman
- J. Anthony
- Albert Isidro-Llobet
In Pharmacology
- Bharat B. Aggarwal
- A. Harvey
- A. Kunnumakkara
- Gisbert Schneider
- J. Anthony
- Shufeng Zhou
- A. Goel
- D. Dias
Citations in the corpus
- A Historical Overview of Natural Products in Drug Discovery (2012, background): “Inspection of the rate of NCEs approvals demonstrates that natural products still contribute to or are involved in ~50% of all small molecule testing between the years 2000–2006 [47].”
- Curcumin as "Curecumin": from kitchen to clinic. (2008, background): “[5] Newman DJ, Cragg GM.”
- Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery (2011, background): “Drug discovery efforts have benefited and are continuing to be benefited from the exploration of multiple lead sources including synthetic chemicals (1–3), biologics (50–53) and natural products (13,44,45).”
- Drug development from marine natural products (2009, background): “Indeed, pharmacologically active compounds from plants and microbes represent an important pipeline for new investigational drug”